Pre-made Obexelimab benchmark antibody ( Whole mAb, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Obexelimab (XmAb 5871) is an anti-CD19 monoclonal antibody that is being developed by Xencor for the treatment of autoimmune disorders including IgG4-related disease, systemic lupus erythematosus and rheumatoid arthritis. Xencor designed the antibody using its XmAb® technology.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-383-1mg	1mg	3090
GMP-Bios-ab-383-10mg	10mg	Inquiry
GMP-Bios-ab-383-100mg	100mg	Inquiry
GMP-Bios-ab-383-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
INN Name	Obexelimab
Target	CD19
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Xencor
Conditions Approved	na
Conditions Active	Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus
Conditions Discontinued	na
Development Tech	XmAb Antibody Engineering Technology